NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer

Dear Investigators participating on NRG-GY012,

 

As you are aware Protocol NRG-GY012 was temporarily suspended to accrual on February 11, 2019 pending NCI CIRB review of the reported Serious non-compliance issue. We were instructed to prepare a letter to be distributed to all participating institutions and a letter for investigators to provide to their patients. Please review the attached letters and follow instructions to inform your patients and to document in the medical records. If you have any questions please contact the Study Chair Helen Mackay at helen.mackay@sunnybrook.ca.

 

-NRG Oncology

NRG-GY012_Dear_Investigator_Letter_040319.pdf

NRG-GY012_Dear_Patient_Letter_040319.pdf

Twitter

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address